Accelerate Diagnostics (AXDX) Competitors $1.07 -0.03 (-2.73%) (As of 12/24/2024 04:00 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends AXDX vs. AKYA, OWLT, MASS, MSAI, CLIR, PRE, OPXS, OMIC, AATC, and RPIDShould you be buying Accelerate Diagnostics stock or one of its competitors? The main competitors of Accelerate Diagnostics include Akoya Biosciences (AKYA), Owlet (OWLT), 908 Devices (MASS), MultiSensor AI (MSAI), ClearSign Technologies (CLIR), Prenetics Global (PRE), Optex Systems (OPXS), Singular Genomics Systems (OMIC), Autoscope Technologies (AATC), and Rapid Micro Biosystems (RPID). These companies are all part of the "measuring and control equipment" industry. Accelerate Diagnostics vs. Akoya Biosciences Owlet 908 Devices MultiSensor AI ClearSign Technologies Prenetics Global Optex Systems Singular Genomics Systems Autoscope Technologies Rapid Micro Biosystems Accelerate Diagnostics (NASDAQ:AXDX) and Akoya Biosciences (NASDAQ:AKYA) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, institutional ownership, analyst recommendations, media sentiment, earnings, dividends, valuation, community ranking and profitability. Which has more volatility & risk, AXDX or AKYA? Accelerate Diagnostics has a beta of 0.56, meaning that its stock price is 44% less volatile than the S&P 500. Comparatively, Akoya Biosciences has a beta of 1.22, meaning that its stock price is 22% more volatile than the S&P 500. Do insiders and institutionals have more ownership in AXDX or AKYA? 17.1% of Accelerate Diagnostics shares are held by institutional investors. Comparatively, 79.4% of Akoya Biosciences shares are held by institutional investors. 43.6% of Accelerate Diagnostics shares are held by insiders. Comparatively, 7.3% of Akoya Biosciences shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. Does the MarketBeat Community believe in AXDX or AKYA? Accelerate Diagnostics received 321 more outperform votes than Akoya Biosciences when rated by MarketBeat users. However, 60.71% of users gave Akoya Biosciences an outperform vote while only 60.37% of users gave Accelerate Diagnostics an outperform vote. CompanyUnderperformOutperformAccelerate DiagnosticsOutperform Votes35560.37% Underperform Votes23339.63% Akoya BiosciencesOutperform Votes3460.71% Underperform Votes2239.29% Does the media prefer AXDX or AKYA? In the previous week, Accelerate Diagnostics had 1 more articles in the media than Akoya Biosciences. MarketBeat recorded 3 mentions for Accelerate Diagnostics and 2 mentions for Akoya Biosciences. Akoya Biosciences' average media sentiment score of 1.87 beat Accelerate Diagnostics' score of 1.25 indicating that Akoya Biosciences is being referred to more favorably in the news media. Company Overall Sentiment Accelerate Diagnostics Positive Akoya Biosciences Very Positive Do analysts rate AXDX or AKYA? Accelerate Diagnostics presently has a consensus target price of $1.00, indicating a potential downside of 6.54%. Akoya Biosciences has a consensus target price of $5.43, indicating a potential upside of 125.25%. Given Akoya Biosciences' higher probable upside, analysts clearly believe Akoya Biosciences is more favorable than Accelerate Diagnostics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Accelerate Diagnostics 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 3.00Akoya Biosciences 0 Sell rating(s) 4 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.43 Is AXDX or AKYA more profitable? Akoya Biosciences has a net margin of -66.77% compared to Accelerate Diagnostics' net margin of -471.83%. Accelerate Diagnostics' return on equity of 0.00% beat Akoya Biosciences' return on equity.Company Net Margins Return on Equity Return on Assets Accelerate Diagnostics-471.83% N/A -191.66% Akoya Biosciences -66.77%-162.99%-32.76% Which has higher valuation and earnings, AXDX or AKYA? Accelerate Diagnostics has higher earnings, but lower revenue than Akoya Biosciences. Akoya Biosciences is trading at a lower price-to-earnings ratio than Accelerate Diagnostics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAccelerate Diagnostics$11.91M2.25-$61.62M-$2.86-0.37Akoya Biosciences$86.82M1.38-$63.32M-$1.18-2.04 SummaryAkoya Biosciences beats Accelerate Diagnostics on 10 of the 19 factors compared between the two stocks. Ad Behind the MarketsWe recommended Palantir in 2021, now we’re recommending this...My research indicates there is only one investment that can meet AI's unprecedented demand for energy.Click to get the name and ticker symbol Get Accelerate Diagnostics News Delivered to You Automatically Sign up to receive the latest news and ratings for AXDX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart AXDX vs. The Competition Export to ExcelMetricAccelerate DiagnosticsAnalytical instruments IndustryMedical SectorNASDAQ ExchangeMarket Cap$26.80M$5.31B$5.24B$9.28BDividend YieldN/A0.43%5.12%4.28%P/E Ratio-0.3725.4187.5417.25Price / Sales2.254.261,164.33121.12Price / CashN/A44.4543.3837.82Price / Book-0.782.204.844.94Net Income-$61.62M$2.05M$121.05M$225.76M7 Day Performance-10.08%-1.67%2.49%3.92%1 Month Performance-35.15%-6.90%17.57%1.71%1 Year Performance-74.28%-30.38%28.57%15.79% Accelerate Diagnostics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)AXDXAccelerate Diagnostics3.6021 of 5 stars$1.07-2.7%$1.00-6.5%-75.3%$26.80M$11.91M-0.37134AKYAAkoya Biosciences2.0445 of 5 stars$2.25-9.6%$5.43+141.3%-51.0%$111.52M$86.82M-1.9190OWLTOwlet1.8154 of 5 stars$4.71+1.5%N/A-18.9%$75.53M$78.58M-1.97106MASS908 Devices2.6145 of 5 stars$1.85-10.4%$8.00+333.6%-79.4%$64.24M$50.23M-1.0460News CoverageGap DownMSAIMultiSensor AI3.6099 of 5 stars$1.93-2.5%$8.00+314.5%-57.6%$58.75M$7.62M0.0035High Trading VolumeCLIRClearSign Technologies3.2307 of 5 stars$1.08-4.4%$6.00+455.6%-8.3%$54.25M$4.28M-9.8210Gap UpPREPrenetics Global2.1983 of 5 stars$5.80+2.7%$9.00+55.2%+3.9%$53.00M$25.56M-1.451OPXSOptex Systems2.3982 of 5 stars$7.48-11.0%N/A+27.5%$51.41M$34.00M12.26122Earnings ReportGap DownOMICSingular Genomics Systems1.5763 of 5 stars$19.31-1.2%$10.75-44.3%+50.3%$48.51M$2.67M-0.55220High Trading VolumeAATCAutoscope TechnologiesN/A$7.99+1.2%N/A+14.0%$43.71M$12.89M9.0740RPIDRapid Micro Biosystems2.247 of 5 stars$0.90flatN/A+5.2%$38.73M$26.17M-0.80193 Related Companies and Tools Related Companies AKYA Competitors OWLT Competitors MASS Competitors MSAI Competitors CLIR Competitors PRE Competitors OPXS Competitors OMIC Competitors AATC Competitors RPID Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:AXDX) was last updated on 12/26/2024 by MarketBeat.com Staff From Our Partners Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happen...Crypto Swap Profits | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Starting with what I call Exec. Order 001. It’s a bombshell law that I believe Trump will sign within minut...Banyan Hill Publishing | SponsoredElon Musk could help pay for your retirementElon Musk is the richest man in the world... And he's pouring trillions into a unique investment.Brownstone Research | SponsoredTSLA *BANG* incoming (bullet in the chamber rn)I just pinpointed 5 dirt-cheap stocks that could soar the second the shot goes off. Thanks to Donald Trump’...StocksToTrade | SponsoredBuy this Stock before Trump Takes Office!To make sure everyone has the opportunity to get in, closes for good at midnight on January 1st, we're lowerin...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Accelerate Diagnostics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Accelerate Diagnostics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
